Actinium Pharmaceuticals (ATNM) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) from a hold rating to a buy rating in a research note issued to investors on Tuesday. The firm currently has $0.75 price target on the biotechnology company’s stock.

According to Zacks, “Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. “

A number of other brokerages also recently commented on ATNM. Maxim Group restated a buy rating and set a $3.00 target price on shares of Actinium Pharmaceuticals in a report on Wednesday, October 25th. HC Wainwright reiterated a buy rating and issued a $6.00 price objective on shares of Actinium Pharmaceuticals in a report on Monday, October 23rd. B. Riley set a $3.00 price objective on Actinium Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, December 12th. Finally, Roth Capital reiterated a buy rating and issued a $6.00 price objective on shares of Actinium Pharmaceuticals in a report on Monday, October 23rd. Five equities research analysts have rated the stock with a buy rating, The stock has a consensus rating of Buy and a consensus price target of $3.75.

Shares of Actinium Pharmaceuticals (NYSEAMERICAN ATNM) traded down $0.02 during trading on Tuesday, hitting $0.71. The company had a trading volume of 292,400 shares, compared to its average volume of 570,192. The company has a market capitalization of $59.22, a P/E ratio of -1.51 and a beta of 41.30. Actinium Pharmaceuticals has a one year low of $0.54 and a one year high of $1.72.

COPYRIGHT VIOLATION WARNING: “Actinium Pharmaceuticals (ATNM) Upgraded at Zacks Investment Research” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/19/actinium-pharmaceuticals-atnm-upgraded-at-zacks-investment-research.html.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).

Get a free copy of the Zacks research report on Actinium Pharmaceuticals (ATNM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply